These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

103 related articles for article (PubMed ID: 12094545)

  • 1. Lack of cell-cycle specific effects of tumor necrosis factor-alpha on tumor cells in vitro: implications for combination tumor therapy with doxorubicin.
    van der Veen AH; ten Hagen TL; Seynhaeve AL; Eggermont AM
    Cancer Invest; 2002; 20(4):499-508. PubMed ID: 12094545
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Combined cytotoxic effects of tumor necrosis factor-alpha with various cytotoxic agents in tumor cell lines that are drug resistant due to mutated p53.
    Sleijfer S; Le TK; de Jong S; Timmer-Bosscha H; Withoff S; Mulder NH
    J Immunother; 1999 Jan; 22(1):48-53. PubMed ID: 9924699
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Synergy is documented in vitro with low-dose recombinant tumor necrosis factor, cisplatin, and doxorubicin in ovarian cancer cells.
    Bonavida B; Tsuchitani T; Zighelboim J; Berek JS
    Gynecol Oncol; 1990 Sep; 38(3):333-9. PubMed ID: 2227544
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Low-dose tumor necrosis factor-alpha augments antitumor activity of stealth liposomal doxorubicin (DOXIL) in soft tissue sarcoma-bearing rats.
    Ten Hagen TL; Van Der Veen AH; Nooijen PT; Van Tiel ST; Seynhaeve AL; Eggermont AM
    Int J Cancer; 2000 Sep; 87(6):829-37. PubMed ID: 10956394
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Synergistic antitumor activity of histamine plus melphalan in isolated limb perfusion: preclinical studies.
    Brunstein F; Hoving S; Seynhaeve AL; van Tiel ST; Guetens G; de Bruijn EA; Eggermont AM; ten Hagen TL
    J Natl Cancer Inst; 2004 Nov; 96(21):1603-10. PubMed ID: 15523089
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Anti-CD20 antibody (IDEC-C2B8, rituximab) enhances efficacy of cytotoxic drugs on neoplastic lymphocytes in vitro: role of cytokines, complement, and caspases.
    Chow KU; Sommerlad WD; Boehrer S; Schneider B; Seipelt G; Rummel MJ; Hoelzer D; Mitrou PS; Weidmann E
    Haematologica; 2002 Jan; 87(1):33-43. PubMed ID: 11801463
    [TBL] [Abstract][Full Text] [Related]  

  • 7. TNF-alpha augments intratumoural concentrations of doxorubicin in TNF-alpha-based isolated limb perfusion in rat sarcoma models and enhances anti-tumour effects.
    van der Veen AH; de Wilt JH; Eggermont AM; van Tiel ST; Seynhaeve AL; ten Hagen TL
    Br J Cancer; 2000 Feb; 82(4):973-80. PubMed ID: 10732774
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Synergistic antitumor effect of TRAIL and doxorubicin on colon cancer cell line SW480.
    Xu LH; Deng CS; Zhu YQ; Liu SQ; Liu DZ
    World J Gastroenterol; 2003 Jun; 9(6):1241-5. PubMed ID: 12800232
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Chemotherapy augments TRAIL-induced apoptosis in breast cell lines.
    Keane MM; Ettenberg SA; Nau MM; Russell EK; Lipkowitz S
    Cancer Res; 1999 Feb; 59(3):734-41. PubMed ID: 9973225
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Reversal of multidrug resistance by transduction of cytokine genes into human colon carcinoma cells.
    Stein U; Walther W; Shoemaker RH
    J Natl Cancer Inst; 1996 Oct; 88(19):1383-92. PubMed ID: 8827016
    [TBL] [Abstract][Full Text] [Related]  

  • 11. TNF-alpha promotes Doxorubicin-induced cell apoptosis and anti-cancer effect through downregulation of p21 in p53-deficient tumor cells.
    Cao W; Chi WH; Wang J; Tang JJ; Lu YJ
    Biochem Biophys Res Commun; 2005 May; 330(4):1034-40. PubMed ID: 15823547
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effect of tumor necrosis factor on human tumor cell lines sensitive and resistant to cytotoxic drugs, and its interaction with chemotherapeutic agents.
    Soranzo C; Perego P; Zunino F
    Anticancer Drugs; 1990 Dec; 1(2):157-63. PubMed ID: 2131048
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Tumor necrosis factor induces doxorubicin resistance to lung cancer cells in vitro.
    Prewitt TW; Matthews W; Chaudhri G; Pogrebniak HW; Pass HI
    J Thorac Cardiovasc Surg; 1994 Jan; 107(1):43-9. PubMed ID: 8283917
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Involvement of the mitochondrion respiratory chain in the synergy achieved by treatment of human ovarian carcinoma cell lines with both tumor necrosis factor-alpha and cis-diamminedichloroplatinum.
    Uslu R; Bonavida B
    Cancer; 1996 Feb; 77(4):725-32. PubMed ID: 8616765
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Sensitivity of drug-resistant human ovarian tumor cell lines to combined effects of tumor necrosis factor (TNF-alpha) and doxorubicin: failure of the combination to modulate the MDR phenotype.
    Safrit JT; Berek JS; Bonavida B
    Gynecol Oncol; 1993 Feb; 48(2):214-20. PubMed ID: 8428693
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Combined activity of interleukin-1 alpha or TNF-alpha and doxorubicin on multidrug resistant cell lines: evidence that TNF and DXR have synergistic antitumor and differentiation-inducing effects.
    Borsellino N; Crescimanno M; Flandina C; Flugy A; D'Alessandro N
    Anticancer Res; 1994; 14(6B):2643-8. PubMed ID: 7872695
    [TBL] [Abstract][Full Text] [Related]  

  • 17. In vivo isolated kidney perfusion with tumour necrosis factor alpha (TNF-alpha) in tumour-bearing rats.
    van der Veen AH; Seynhaeve AL; Breurs J; Nooijen PT; Marquet RL; Eggermont AM
    Br J Cancer; 1999 Feb; 79(3-4):433-9. PubMed ID: 10027309
    [TBL] [Abstract][Full Text] [Related]  

  • 18. 2-Deoxy-D-glucose enhances sensitivity of human histiocytic lymphoma U937 cells to apoptosis induced by tumor necrosis factor.
    Halicka HD; Ardelt B; Li X; Melamed MM; Darzynkiewicz Z
    Cancer Res; 1995 Jan; 55(2):444-9. PubMed ID: 7812976
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Silibinin strongly synergizes human prostate carcinoma DU145 cells to doxorubicin-induced growth Inhibition, G2-M arrest, and apoptosis.
    Tyagi AK; Singh RP; Agarwal C; Chan DC; Agarwal R
    Clin Cancer Res; 2002 Nov; 8(11):3512-9. PubMed ID: 12429642
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Inhibition of the tumour necrosis factor-alpha autocrine loop enhances the sensitivity of multiple myeloma cells to anticancer drugs.
    Tsubaki M; Komai M; Itoh T; Imano M; Sakamoto K; Shimaoka H; Ogawa N; Mashimo K; Fujiwara D; Takeda T; Mukai J; Sakaguchi K; Satou T; Nishida S
    Eur J Cancer; 2013 Nov; 49(17):3708-17. PubMed ID: 23932230
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.